Literature DB >> 20302675

Case of a sigmoid colon cancer with metachronous metastases to the mesorectum and the abdominal wall.

John Kalaitzis1, George Filippou, Adamantia Zizi-Sermpetzoglou, Athanasios Marinis, Andreas Hadjimarcou, Nikolaos Paschalidis, Spyros Rizos.   

Abstract

BACKGROUND: Sigmoid colon cancer metachronous metastases commonly occur in the liver and lungs with sporadic reports also to the spleen, stomach, thyroid gland, abdominal wall and upper urinary tract. This is a rare case of metachronous metastases invading the mesorectum and the abdominal wall. CASE
PRESENTATION: A 72-year-old female underwent sigmoidectomy for stage I (T2N0 M0) sigmoid colon cancer in May 2008. In June 2009, an abdominal computed tomography scan revealed a tumor 2 cm in size at the lower anterior mesorectum and a second mass 2 cm in size at the anterior abdominal wall midline. Total colonoscopy showed no mucosal lesion. The serum carcinoembryonic antigen level was normal. A biopsy of the mesorectum tumor showed similar histologic characteristics with the primary tumor. Since no other site of recurrence was identified, an abdominoperineal resection was attempted. During the operation and after the removal of the incision recurrence, sinus bradycardia and signs of myocardial ischemia were noticed. A loop transverse colostomy was immediately perfomed and the operation was terminated. Postoperative cardiologic examination revealed an acute myocardium infract. Chemo-radiation of the mesorectum tumor and re-evaluation for surgical excision was decided.
CONCLUSION: Metachronous metastasis of the mesorectum from sigmoid colon cancer is extremely rare. Although patterns of lymphatic spread from rectal cancer to sigmoid colon have recently been demonstrated, there is no evidence of metachronous mesorectum invasion from sigmoid colon cancer. This could be the issue for future trials.

Entities:  

Mesh:

Year:  2010        PMID: 20302675      PMCID: PMC2848135          DOI: 10.1186/1477-7819-8-17

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  14 in total

1.  Rectal carcinoma metastatic to the thyroid gland.

Authors:  T W Mesko; J Friedman; H Sendzischew; D D Nixon
Journal:  J Laryngol Otol       Date:  1996-02       Impact factor: 1.469

2.  Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection.

Authors:  Natalie E Joseph; Elin R Sigurdson; Alexandra L Hanlon; Hao Wang; Robert J Mayer; John S MacDonald; Paul J Catalano; Daniel G Haller
Journal:  Ann Surg Oncol       Date:  2003-04       Impact factor: 5.344

Review 3.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

Authors:  C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

Review 4.  The staging of colorectal cancer: 2004 and beyond.

Authors:  Carolyn C Compton; Frederick L Greene
Journal:  CA Cancer J Clin       Date:  2004 Nov-Dec       Impact factor: 508.702

5.  For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.

Authors:  S Caplin; J P Cerottini; F T Bosman; M T Constanda; J C Givel
Journal:  Cancer       Date:  1998-08-15       Impact factor: 6.860

6.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Authors:  T E Le Voyer; E R Sigurdson; A L Hanlon; R J Mayer; J S Macdonald; P J Catalano; D G Haller
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

7.  Metastasis to the sigmoid or sigmoid mesenteric lymph nodes from rectal cancer.

Authors:  In Ja Park; Gyu-Seog Choi; Kyung Hoon Lim; Byung Mo Kang; Soo Han Jun
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

8.  Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group.

Authors:  R M Goldberg; T R Fleming; C M Tangen; C G Moertel; J S Macdonald; D G Haller; J A Laurie
Journal:  Ann Intern Med       Date:  1998-07-01       Impact factor: 25.391

9.  Optimum lymph node dissection in clinical T1 and clinical T2 colorectal cancer.

Authors:  Yutaka Kobayashi; Shin Fujita; Tomohiro Yamaguchi; Seiichiro Yamamoto; Takayuki Akasu; Yoshihiro Moriya
Journal:  Dis Colon Rectum       Date:  2009-05       Impact factor: 4.585

10.  Isolated metachronous splenic metastasis from synchronous colon cancer.

Authors:  Rasim Gencosmanoglu; Fugen Aker; Gozde Kir; Nurdan Tozun
Journal:  World J Surg Oncol       Date:  2006-07-06       Impact factor: 2.754

View more
  4 in total

1.  Metachronous Mesorectal Recurrence after Colectomy for Ascending Colon Cancer.

Authors:  Matthew Mackowsky; Ashley Toussaint; Kevin Clarke; Rachel Hudacko
Journal:  Case Rep Oncol       Date:  2020-06-11

2.  Long-term survival of a patient with metachronous rectal metastasis from primary cecal cancer who underwent repetitive resection and chemotherapy: a case report.

Authors:  Jiro Shimazaki; Takeshi Nakachi; Takanobu Tabuchi; Hideyuki Ubukata; Takafumi Tabuchi
Journal:  World J Surg Oncol       Date:  2014-04-23       Impact factor: 2.754

3.  Metachronous rectal metastasis from primary transverse colon cancer: a case report.

Authors:  Shigehiro Kojima; Tsuguo Sakamoto; Yuko Nagai; Masayuki Honda; Fumihiro Ogawa
Journal:  Surg Case Rep       Date:  2018-08-09

4.  Anterior abdominal wall metastasis following curative resection and chemoradiation of rectal cancer masquerading as a desmoid tumour: A clinical conundrum.

Authors:  Ajay Raveendranadh; Meera Goutham; Chiranth Gowda; Kshama Hegde; Vidya Monappa; Gabriel Rodrigues
Journal:  J Taibah Univ Med Sci       Date:  2021-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.